Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hzVSF-v13 for COVID-19 pneumonia
2020-003614-13Phase 2Completed
- Sponsor
- ImmuneMed Inc.
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of burfiralimab in coronavirus pneumonia and coronavirus disease 2019 (COVID-19) (3 arms), sponsored by ImmuneMed Inc. Primary endpoint: Safety endpoints. Started Nov 2020; status: completed.
02
Drugs
burfiralimab
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-003614-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003614-13.